May 15, 2017 / 11:34 AM / 2 months ago

BRIEF-Summit Therapeutics says completes enrolment of PhaseOut DMD

1 Min Read

May 15 (Reuters) - Summit Therapeutics Plc

* Summit completes enrolment of PhaseOut DMD, a phase 2 clinical trial of ezutromid in patients with dmd

* Summit Therapeutics - with dosing of last patient in trial, co has triggered $22 million milestone payment

* $22 million milestone payment is part of company's licence and collaboration agreement with Sarepta Therapeutics Inc Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below